Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619035 | 1.00 | REN (0.48) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5621922 | 0.88 | REN (0.52) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5621919 | 0.88 | REN (0.52) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5619905 | 0.86 | REN (0.48) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5619911 | 0.86 | REN (0.48) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5853384 | 0.83 | HPGD (0.40) | REN | |
| SCHEMBL14602362 | 0.83 | BACE1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5225345 | 0.81 | KLK5 (0.53) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5637001 | 0.80 | BACE1 (0.53) | — | |
| SCHEMBL5637007 | 0.80 | BACE1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | disclosed |
| EP-1448516-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045903-A1 | HYDROXYETHYLENE COMPOUNDS WITH ASP2 INHIBITORY ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | REN 2404/4885PSEN1 6/4885PSEN2 2/4885 |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | REN 1933/4885PSEN1 4/4885PSEN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.